Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib +/- Dexamethasone in Multiple Myeloma
NCT02211014Phase 1Completed
- Sponsor
- Acerta Pharma
- Start
- Feb 2015
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of acalabrutinib in multiple myeloma (MM) (2 arms), sponsored by Acerta Pharma. Primary endpoint: Safety Profile of Acalabrutinib With and Without Dexamethasone up to 48 weeks. Started Feb 2015; status: completed.
02
Drugs
acalabrutinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02211014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211014.